Teleflex (TFX)
(Delayed Data from NYSE)
$206.71 USD
0.00 (0.00%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $206.79 +0.08 (0.04%) 7:58 PM ET
4-Sell of 5 4
B Value D Growth B Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
TFX 206.71 0.00(0.00%)
Will TFX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for TFX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TFX
Teleflex (TFX) Debuts the New Unified UroLift 2 System With ATC
Is ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) a Strong ETF Right Now?
TFX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why You Should Retain Teleflex (TFX) Stock for Now
Should ALPS O'Shares U.S. Small-Cap Quality Dividend ETF (OUSM) Be on Your Investing Radar?
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Falls
Other News for TFX
Teleflex Announces First Quarter 2024 Earnings Conference Call Information
RBC Capital Sticks to Its Buy Rating for Teleflex (TFX)
(TFX) - Analyzing Teleflex's Short Interest
DDL Expands its Offerings with Addition of Consulting Services Focused on Packaging Process Development
Teleflex Incorporated Introduces the UroLift™ 2 System With Advanced Tissue Control, a Revolutionary Unified Platform Designed to Treat All Prostate Types